What Is Retatrutide?

What is retatrutide, how does it work, and what do the latest retatrutide clinical trial results actually mean for people living with obesity?

In this episode of Weight & Measure with Mike and Zach, Dr. Ania Jastreboff and Ted Kyle join Mike Donnelly-Boylen and Zach Niemiec for a patient-centered deep dive into retatrutide, the investigational GLP-1/GIP/glucagon triple agonist being studied for obesity and type 2 diabetes.

Dr. Jastreboff is a Yale physician-scientist, a leading obesity researcher, and has been deeply involved in the clinical development of retatrutide. She presented the first Phase 3 obesity results from TRIUMPH-1 at the American Diabetes Association Scientific Sessions and is co-author of Enough with Oprah Winfrey.

Ted Kyle is a pharmacist and longtime obesity advocate who brings together obesity science, policy, advocacy and lived experience.

Dr. Jastreboff explains how GLP-1, GIP and glucagon work, why researchers combined all three receptors into one medication, and why activating the glucagon receptor may make sense even though glucagon is commonly associated with increasing blood glucose.

We then break down the TRIUMPH-1 retatrutide results, including:

• How much weight participants lost with retatrutide
• Why results may differ between obesity and type 2 diabetes
• Retatrutide doses, titration, side effects and discontinuation
• Whether everyone needs the highest retatrutide dose
• How clinical-trial dosing differs from real-world obesity treatment

We tackle one of the biggest questions surrounding GLP-1 medications: muscle loss.

Dr. Jastreboff explains the important difference between lean mass and skeletal muscle, what body-composition studies can actually measure, and what we know so far about retatrutide compared with semaglutide and tirzepatide.

The conversation goes beyond the number on the scale to explore findings involving knee osteoarthritis, obstructive sleep apnea, liver fat, metabolic health and other complications of obesity.

We also ask whether comparing retatrutide vs tirzepatide vs metabolic & bariatric surgery misses the bigger point. Could the future of obesity care involve choosing and combining treatments based on the individual rather than asking which treatment “wins”?

Ted explains Lilly’s planned Biologics License Application (BLA) for retatrutide, what biologic status could mean for future competition and why we still cannot assume what retatrutide will eventually cost.

We also discuss expanded access to retatrutide before FDA approval, who it is intended for, and why retatrutide remains an investigational medication.

Finally, Dr. Jastreboff connects the science to Enough, her book with Oprah Winfrey.

What is the “Enough Point”? Is the goal of obesity treatment always greater weight loss? Or should success be individualized around health, function, quality of life and the outcomes that matter to the person receiving treatment?

What is retatrutide? How does it compare with tirzepatide? Does retatrutide cause muscle loss? When will retatrutide be available? And what do we still not know?

This episode separates what the science actually shows from the speculation surrounding one of the most talked-about obesity medications in development.

More Science. Less Stigma.

Retatrutide is investigational and is not FDA approved.

#Retatrutide #GLP1 #Tirzepatide #Obesity #ObesityMedicine #TRIUMPH1